Dana-Farber Cancer Institute's Kimberly Stegmaier led a study published yesterday in PNAS that uses a "signature-based screening approach" to identify hits in neuroblastoma treatment. Her team used gene expression analysis to screen a small molecule library, and the top hit was all-trans-retinoic acid.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.